These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16806271)

  • 21. Defining mild cognitive impairment in Parkinson's disease.
    Caviness JN; Driver-Dunckley E; Connor DJ; Sabbagh MN; Hentz JG; Noble B; Evidente VG; Shill HA; Adler CH
    Mov Disord; 2007 Jul; 22(9):1272-7. PubMed ID: 17415797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What's in the pipeline for the treatment of Parkinson's disease?
    Sommer DB; Stacy MA
    Expert Rev Neurother; 2008 Dec; 8(12):1829-39. PubMed ID: 19086879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivastigmine in Parkinson's disease dementia.
    Lalli S; Albanese A
    Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of dementia associated with Parkinson's disease.
    Emre M
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S457-61. PubMed ID: 18267283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of early Parkinson's disease. Part 1.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):193-205. PubMed ID: 19176960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
    Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
    Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When should drug treatment be started for people with dementia?
    Singh B; O'Brien JT
    Maturitas; 2009 Mar; 62(3):230-4. PubMed ID: 19201114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of non-motor symptoms in advanced Parkinson disease.
    Truong DD; Bhidayasiri R; Wolters E
    J Neurol Sci; 2008 Mar; 266(1-2):216-28. PubMed ID: 17804018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment.
    Kulisevsky J; Pagonabarraga J
    Mov Disord; 2009 Jun; 24(8):1103-10. PubMed ID: 19353727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early neuropsychological detection and the characteristics of Parkinson's disease associated with mild dementia.
    Song IU; Kim JS; Jeong DS; Song HJ; Lee KS
    Parkinsonism Relat Disord; 2008 Nov; 14(7):558-62. PubMed ID: 18328767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychosis in Parkinson's disease.
    Wint DP; Okun MS; Fernandez HH
    J Geriatr Psychiatry Neurol; 2004 Sep; 17(3):127-36. PubMed ID: 15312276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of behavioural symptoms and dementia in Parkinson's disease.
    Hanagasi HA; Emre M
    Fundam Clin Pharmacol; 2005 Apr; 19(2):133-46. PubMed ID: 15810893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New pharmacological options for treating advanced Parkinson's disease.
    Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
    Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current management of Parkinson's disease.
    Salawu F; Olokoba A; Danburam A
    Ann Afr Med; 2010; 9(2):55-61. PubMed ID: 20587924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity of cognitive dysfunction in Parkinson's disease: a cohort study.
    Verleden S; Vingerhoets G; Santens P
    Eur Neurol; 2007; 58(1):34-40. PubMed ID: 17483583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease.
    Caviness JN; Hentz JG; Evidente VG; Driver-Dunckley E; Samanta J; Mahant P; Connor DJ; Sabbagh MN; Shill HA; Adler CH
    Parkinsonism Relat Disord; 2007 Aug; 13(6):348-54. PubMed ID: 17347022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument.
    Kalbe E; Calabrese P; Kohn N; Hilker R; Riedel O; Wittchen HU; Dodel R; Otto J; Ebersbach G; Kessler J
    Parkinsonism Relat Disord; 2008; 14(2):93-101. PubMed ID: 17707678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
    Szeto JY; Lewis SJ
    Curr Neuropharmacol; 2016; 14(4):326-38. PubMed ID: 26644155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.